Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation
Public ClinicalTrials.gov record NCT01240876. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety and Efficacy of CEP-37247 Administered at Single Doses of 0.5, 1, 3, 6, or 12 mg by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation
Study identification
- NCT ID
- NCT01240876
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Cephalon
- Industry
- Enrollment
- 98 participants
Conditions and interventions
Conditions
Interventions
- CEP-37247 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Feb 28, 2013
- Completion
- Mar 31, 2013
- Last update posted
- Jul 20, 2016
2011 – 2013
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 22 | La Mesa | California | — | — |
| Teva Investigational Site 18 | Laguna Hills | California | — | — |
| Teva Investigational Site 19 | Pasadena | California | — | — |
| Teva Investigational Site 2 | Pasadena | California | — | — |
| Teva Investigational Site 14 | Orlando | Florida | — | — |
| Teva Investigational Site 5 | Sarasota | Florida | — | — |
| Teva Investigational Site 10 | Marietta | Georgia | — | — |
| Teva Investigational Site 13 | Marietta | Georgia | — | — |
| Teva Investigational Site 9 | Bloomington | Illinois | — | — |
| Teva Investigational Site 15 | Overland Park | Kansas | — | — |
| Teva Investigational Site 8 | Shreveport | Louisiana | — | — |
| Teva Investigational Site 20 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 16 | Dayton | Ohio | — | — |
| Teva Investigational Site 21 | Eugene | Oregon | — | — |
| Teva Investigational Site 17 | Altoona | Pennsylvania | — | — |
| Teva Investigational Site 1 | Greenville | South Carolina | — | — |
| Teva Investigational Site 11 | North Charleston | South Carolina | — | — |
| Teva Investigational Site 6 | Spartanburg | South Carolina | — | — |
| Teva Investigational Site 4 | Orem | Utah | — | — |
| Teva Investigational Site 3 | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01240876, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2016 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01240876 live on ClinicalTrials.gov.